Subject(s)
Bile Duct Neoplasms/diagnostic imaging , Clinical Decision-Making , Computer Simulation , Imaging, Three-Dimensional , Klatskin Tumor/diagnostic imaging , Software , Bile Duct Neoplasms/pathology , Bile Duct Neoplasms/surgery , Humans , Klatskin Tumor/pathology , Klatskin Tumor/surgery , Magnetic Resonance Imaging , Precision Medicine , Preoperative Care , Retrospective Studies , Tomography, X-Ray ComputedABSTRACT
Background Pancreatectomy plus celiac axis resection (CAR) is performed in patients with locally advanced pancreatic cancer. The morbidity rates are high, and no survival benefit has been confirmed. It is not known at present whether it is the type of pancreatectomy, or CAR itself, that is the reason for the high complication rates. Methods Observational retrospective multicenter study. Inclusion criteria: patient undergoing TP, PD or DP plus CAR for a pancreatic cancer. Results Sixty-two patients who had undergone pancreatic cancer surgery (PD,TP or DP) plus CAR were studied. Group 1: 17 patients who underwent PD/TP-CAR (13TP/4PD); group 2: 45 patients who underwent DP-CAR. Groups were mostly homogeneous. Operating time was longer in the PD/TP group, while operative complications did not differ statistically in the two groups. The number of lymph nodes removed was higher in the PD/TP group (26.5 vs 17.3), and this group also had a higher positive node ratio (17.9% vs 7.6%). There were no statistical differences in total or disease-free survival between the two groups. Conclusion It seems that CAR, and not the type of pancreatectomy, influences morbidity and mortality in this type of surgery. International multicenter studies with larger numbers of patients are now needed to validate the data presented here (AU)
Subject(s)
Humans , Male , Female , Middle Aged , Celiac Artery/surgery , Pancreatectomy/methods , Pancreatic Neoplasms/surgery , Retrospective Studies , Treatment Outcome , Disease-Free Survival , Lymph Node Excision/statistics & numerical data , Neoplasm Invasiveness , Pancreatectomy/adverse effects , Pancreatectomy/mortality , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , SpainABSTRACT
BACKGROUND: Pancreatectomy plus celiac axis resection (CAR) is performed in patients with locally advanced pancreatic cancer. The morbidity rates are high, and no survival benefit has been confirmed. It is not known at present whether it is the type of pancreatectomy, or CAR itself, that is the reason for the high complication rates. METHODS: Observational retrospective multicenter study. INCLUSION CRITERIA: patient undergoing TP, PD or DP plus CAR for a pancreatic cancer. RESULTS: Sixty-two patients who had undergone pancreatic cancer surgery (PD,TP or DP) plus CAR were studied. Group 1: 17 patients who underwent PD/TP-CAR (13TP/4PD); group 2: 45 patients who underwent DP-CAR. Groups were mostly homogeneous. Operating time was longer in the PD/TP group, while operative complications did not differ statistically in the two groups. The number of lymph nodes removed was higher in the PD/TP group (26.5 vs 17.3), and this group also had a higher positive node ratio (17.9% vs 7.6%). There were no statistical differences in total or disease-free survival between the two groups. CONCLUSION: It seems that CAR, and not the type of pancreatectomy, influences morbidity and mortality in this type of surgery. International multicenter studies with larger numbers of patients are now needed to validate the data presented here.
Subject(s)
Celiac Artery/surgery , Pancreatectomy/methods , Pancreatic Neoplasms/surgery , Body Mass Index , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lymph Node Excision/statistics & numerical data , Male , Middle Aged , Neoplasm Invasiveness/pathology , Operative Time , Pancreatectomy/adverse effects , Pancreatectomy/mortality , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Postoperative Complications , Retrospective Studies , Spain , Treatment OutcomeABSTRACT
This study investigated the occurrence of 135 contaminants of emerging concern (CECs) - pharmaceuticals, pesticides, a set of endocrine disrupting compounds (EDCs) (parabens, bisphenols, hormones, triazoles, organophosphorus flame retardants and triclosan), UV-filters, perfluoroalkyl substances (PFASs) and halogenated flame retardants (HFRs) - in 59 fish samples, collected in 2010 in 4 Spanish Rivers (Guadalquivir, Júcar, Ebro and Llobregat). Of the 135 CECs, 76 including 8 pharmaceuticals, 25 pesticides, 10 EDCs, 5 UV-filters, 15 PFASs and 13 HFRs were detected. Pharmaceuticals were the less frequently found and at lower concentrations. Pesticides, EDCs, UV-filters, PFASs and HFRs were detected more frequently (>50% of the samples). The maximum concentrations were 15â¯ng/g dry weight (dw) for pharmaceuticals (diclofenac), 840â¯ng/g dw for pesticides (chlorpyrifos), 224â¯ng/g dw for EDCs (bisphenol A), 242â¯ng/g dw for UV-filters (EHMC), 1738â¯ng/g dw for PFASs (PFHxA) and 64â¯ng/g dw for HFRs (Dec 602). The contaminants detected in fish are commonly detected also in sediments. In light of current knowledge, the risk assessment revealed that there was no risk for humans related to the exposure to CECs via freshwater fish consumption. However, results provide detailed information on the mixtures of CECs accumulated that would be very useful to identify their effects on aquatic biota.
Subject(s)
Environmental Monitoring , Fishes/metabolism , Water Pollutants, Chemical/metabolism , Animals , Endocrine Disruptors/analysis , Endocrine Disruptors/metabolism , Flame Retardants/analysis , Flame Retardants/metabolism , Fresh Water/chemistry , Geologic Sediments/chemistry , Halogenated Diphenyl Ethers/analysis , Halogenated Diphenyl Ethers/metabolism , Pesticides/analysis , Pesticides/metabolism , Rivers/chemistry , Spain , Water Pollutants, Chemical/analysisABSTRACT
BACKGROUND: Anastomotic leakage of pancreaticojejunostomy (PJ) remains the single most important source of morbidity after pancreaticoduodenectomy (PD). The primary aim of this randomized clinical trial comparing PG with PJ after PD was to test the hypothesis that invaginated PG would result in a lower rate and severity of pancreatic fistula. METHODS: Patients undergoing PD were randomized to receive either a duct-to-duct PJ or a double-layer invaginated PG. The primary endpoint was the rate of pancreatic fistula, using the definition of the International Study Group on Pancreatic Fistula. Secondary endpoints were the evaluation of severe abdominal complications (Clavien-Dindo grade IIIa or above), endocrine and exocrine function. RESULTS: Of 123 patients randomized, 58 underwent PJ and 65 had PG. The incidence of pancreatic fistula was significantly higher following PJ than for PG (20 of 58 versus 10 of 65 respectively; P = 0.014), as was the severity of pancreatic fistula (grade A: 2 versus 5 per cent; grade B-C: 33 versus 11 per cent; P = 0.006). The hospital readmission rate for complications was significantly lower after PG (6 versus 24 per cent; P = 0.005), weight loss was lower (P = 0.025) and exocrine function better (P = 0.022). CONCLUSION: The rate and severity of pancreatic fistula was significantly lower with this PG technique compared with that following PJ. REGISTRATION NUMBER: ISRCTN58328599 (http://www.controlled-trials.com).
Subject(s)
Gastrostomy/adverse effects , Pancreatectomy/adverse effects , Pancreatic Fistula/prevention & control , Pancreaticoduodenectomy/adverse effects , Adult , Aged , Aged, 80 and over , Drainage/methods , Female , Gastrostomy/methods , Humans , Length of Stay , Male , Middle Aged , Pancreatectomy/methods , Pancreaticoduodenectomy/methods , Postoperative Complications/prevention & control , Prospective Studies , Treatment OutcomeABSTRACT
Chronic pancreatitis (CP) is a relatively uncommon, complex and heterogeneous disease. The absence of a gold standard applicable to the initial phases of CP makes its early diagnosis difficult. Some of its complications, particularly chronic pain, can be difficult to manage. There is much variability in the diagnosis and treatment of CP and its complications amongst centers and professionals. The Spanish Pancreatic Club has developed a consensus on the management of CP. Two coordinators chose a multidisciplinary panel of 24 experts on this disease. A list of questions was drafted, and two experts reviewed each question. Then, a draft was produced and shared with the entire panel of experts and discussed in a face-to-face meeting. This first part of the consensus addresses the diagnosis of CP and its complications.
Subject(s)
Pancreatitis, Chronic/diagnosis , Alcoholism/complications , Autoimmune Diseases , Blood Glucose/metabolism , Diabetes Mellitus/etiology , Glycated Hemoglobin/metabolism , Humans , Pancreas/diagnostic imaging , Pancreatitis, Chronic/complications , Pancreatitis, Chronic/diagnostic imaging , Smoking/adverse effects , UltrasonographyABSTRACT
Chronic pancreatitis (CP) is a complex disease with a wide range of clinical manifestations. This range comprises from asymptomatic patients to patients with disabling symptoms or complications. The management of CP is frequently different between geographic areas and even medical centers. This is due to the paucity of high quality studies and clinical practice guidelines regarding its diagnosis and treatment. The aim of the Spanish Pancreatic Club was to give current evidence-based recommendations for the management of CP. Two coordinators chose a multidisciplinary panel of 24 experts on this disease. These experts were selected according to clinical and research experience in CP. A list of questions was made and two experts reviewed each question. A draft was later produced and discussed with the entire panel of experts in a face-to-face meeting. The level of evidence was based on the ratings given by the Oxford Centre for Evidence-Based Medicine. In the second part of the consensus, recommendations were given regarding the management of pain, pseudocysts, duodenal and biliary stenosis, pancreatic fistula and ascites, left portal hypertension, diabetes mellitus, exocrine pancreatic insufficiency, and nutritional support in CP.
Subject(s)
Pancreatitis, Chronic/therapy , Acetaminophen/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cholangiopancreatography, Endoscopic Retrograde , Constriction, Pathologic/therapy , Drainage , Evidence-Based Medicine , Exocrine Pancreatic Insufficiency/therapy , Nutritional Status , Pain Management , Pancreatic Pseudocyst/therapy , Pancreatitis, Chronic/diet therapy , Pancreatitis, Chronic/surgeryABSTRACT
Hydrodynamic injection is an efficient procedure for liver gene therapy in rodents but with limited efficacy in large animals, using an 'in vivo' adapted regional hydrodynamic gene delivery system. We study the ability of this procedure to mediate gene delivery in human liver segments obtained by surgical resection. Watertight liver segments were retrogradely injected from hepatic vein with a saline solution containing a plasmid bearing the enhanced green fluorescent protein (eGFP) gene, under different conditions of flow rate (1, 10 and 20 ml s(-1)) and final perfused volume. Samples were cultured for 1 to 2 days and used for microscopy and molecular analysis of gene expression. The fluorescent and immunohistochemistry studies indicated that in segments injected at ≥10 ml s(-1), good and wide gene expression was present in the liver sections and the molecular analysis reinforced the histological observation in a quantitative manner (index of apparent gene delivery: 10(2)-10(4) eGFP DNA copy per 100 pg of total DNA; transcription index: 10(5)-2 × 10(6) eGFP RNA copy per 100 ng of total RNA). In addition, injected gold nanoparticles (15 nm diameter) suggested that DNA delivery to hepatocytes must involve a facilitated permeation process without membrane disruption. In summary, we show that retrograde venous injection of watertight human liver segment is an anadromous procedure that results in wide liver gene delivery and good gene expression. However, additional studies will be necessary to clarify the influence of the prolonged ischemia injury to hepatocytes in our model.
Subject(s)
Catheterization , Gene Transfer Techniques , Hydrodynamics , Liver/metabolism , Genetic Therapy/methods , Green Fluorescent Proteins/genetics , Hepatic Veins , Humans , Injections, Intravenous , PlasmidsABSTRACT
OBJECTIVE: The clinical characteristics of patients with relapsing anti-NMDA receptor (NMDAR) encephalitis are not well-defined. In this study, we report the clinical profile and outcome of relapses in a series of anti-NMDAR encephalitis. METHODS: We did a retrospective review of relapses that occurred in 25 patients with anti-NMDAR encephalitis. Relapses were defined as any new psychiatric or neurologic syndrome, not explained by other causes, which improved after immunotherapy or, less frequently, spontaneously. RESULTS: A total of 13 relapses were identified in 6 patients. Four of them had several, 2 to 4, relapses. There was a median delay of 2 years (range 0.5 to 13 years) for the first relapse. Median relapse rate was 0.52 relapses/patient-year. Relapse risk was higher in patients who did not receive immunotherapy in the first episode (p = 0.009). Most cases (53%) presented partial syndromes of the typical anti-NMDAR encephalitis. Main symptoms of relapses were speech dysfunction (61%), psychiatric (54%), consciousness-attention disturbance (38%), and seizures (31%). Three relapses (23%) presented with isolated atypical symptoms suggestive of brainstem-cerebellar involvement. An ovarian teratoma was detected at relapse in only 1 patient (17%). Relapses did not add residual deficit to that caused by the first episode. CONCLUSIONS: Relapses in anti-NMDAR encephalitis are common (24%). They may occur many years after the initial episode. Relapses may present with partial aspects or with isolated symptoms of the full-blown syndrome. Immunotherapy at first episode reduces the risk of relapses.
Subject(s)
Autoantibodies/biosynthesis , Encephalitis/immunology , Receptors, N-Methyl-D-Aspartate/immunology , Adolescent , Adult , Autoantibodies/blood , Child , Child, Preschool , Encephalitis/diagnosis , Female , Follow-Up Studies , HEK293 Cells , Humans , Immunotherapy/methods , Infant , Male , Middle Aged , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/blood , Recurrence , Retrospective Studies , Young AdultABSTRACT
BACKGROUND: γ-Aminobutyric acid-B receptor antibodies (GABA(B)R-ab) were recently described in 15 patients with limbic encephalitis (LE), associated with small-cell lung cancer (SCLC) or with concurrent glutamic acid decarboxylase (GAD) antibodies. We analyzed the frequency of GABA(B)R-ab in 147 patients with LE or neurologic syndromes associated with GAD-ab. METHODS: We examined the presence of GABA(B)R-ab in 70 patients with LE (33 paraneoplastic with onconeural antibodies, 18 paraneoplastic without onconeural antibodies [5 with Gad-ab], and 19 idiopathic with either GAD-ab [5 patients] or seronegative) and 77 patients with GAD-ab-associated neurologic syndromes other than LE (29 stiff-person syndrome, 28 cerebellar ataxia, 14 epilepsy, and 6 with diverse paraneoplastic neurologic syndromes). GABA(B)R-ab were analyzed in serum or CSF by indirect immunofluorescence on HEK293 cells transfected with GABA(B1) and GABA(B2) receptor subunits. RESULTS: GABA(B)R-ab were detected in 10 of the 70 patients with LE (14%). Eight had SCLC and 2 were idiopathic. One of the 8 patients with LE with SCLC had an additional onconeural antibody (Hu) and 2 GAD-ab. GABA(B)R-ab were identified in 7 (70%) of the 10 patients with LE and SCLC without onconeural antibodies. GABA(B)R-ab antibodies were not found in patients with GAD-ab and stiff-person syndrome, idiopathic cerebellar ataxia, or epilepsy. However, one patient with GAD-ab, paraneoplastic cerebellar ataxia, and anaplastic carcinoid of the thymus also presented GABA(B)R-ab. CONCLUSIONS: GABA(B)R-ab are the most common antibodies found in LE associated with SCLC previously considered "seronegative." In patients with GAD-ab, the frequency of GABA(B)R-ab is low and only observed in the context of cancer.
Subject(s)
Antibodies/blood , Glutamate Decarboxylase/blood , Limbic Encephalitis/blood , Receptors, GABA-B/blood , Aged , Antibodies/immunology , Female , Follow-Up Studies , Glutamate Decarboxylase/immunology , HEK293 Cells , Humans , Limbic Encephalitis/immunology , Male , Middle Aged , Nervous System Diseases/blood , Nervous System Diseases/immunology , Receptors, GABA-B/immunologyABSTRACT
INTRODUCTION: The description of a highly sensitive and specific biomarker for neuromyelitis optica (NMO-IgG/aquaporin-4 antibody) extended the clinical spectrum of NMO to limited forms such as optic neuritis (ON) and longitudinally extensive myelitis (LEM). OBJECTIVE: To asses the sensitivity and specificity of our assay, and to describe the clinical characteristics of the patients who were tested for NMO-IgG. METHODS: NMO-IgG was analysed by immunohistochemistry and confirmed by assay on HEK cells transfected with aquaporin-4. The clinical information was obtained from forms filled in by the referring neurologists. RESULTS: A total of 580 samples from 518 patients were analysed from November 2005 to September 2008. Clinical information was available from 358 (68%) patients. All 33 (100%) positive cases were followed up. Twenty-eight of the 43 (65%) patients diagnosed with NMO by the revised criteria of 2006 were positive; the sensitivity was 62.5% when applying the same criteria, but discounting the criterion of NMO-IgG status, or 57% when applying the criteria of 1999. NMO-IgG was detected in 3 (13%) of the recurrent LEM and 2 (4%) of the recurrent ON. NMO-IgG was not detected in the remaining patients (96 with a final diagnosis of multiple sclerosis; 80 with myelitis; 28 with non-recurrent ON; and 33 other diagnosis). CONCLUSIONS: No false positive cases were found in this large and non-selected study. NMO-IgG positive cases were mostly associated with NMO, and only in a low percentage with recurrent ON or LEM.
Subject(s)
Aquaporin 4/immunology , Autoantibodies/immunology , Immunoglobulin G/immunology , Neuromyelitis Optica , Adolescent , Adult , Age of Onset , Aged , Aquaporin 4/genetics , Biomarkers/metabolism , Cell Line , Child , Female , Humans , Immunohistochemistry , Male , Middle Aged , Neuromyelitis Optica/immunology , Neuromyelitis Optica/pathology , Neuromyelitis Optica/physiopathology , Retrospective Studies , Sensitivity and Specificity , Young AdultSubject(s)
Antibodies/blood , Brain/metabolism , Encephalitis/blood , Encephalitis/immunology , Receptors, AMPA/immunology , Aged , Brain/pathology , Brain/physiopathology , Cell Line, Transformed , Encephalitis/drug therapy , Encephalitis/pathology , Female , Humans , Middle Aged , Transfection/methodsABSTRACT
Introducción: Los anticuerpos IgG-NMO se han demostrado sensibles y específicos para el diagnóstico de neuromielitis óptica (NMO) y han permitido ampliar el espectro clínico a formas limitadas como neuritis óptica (NO) o mielitis longitudinalmente extensas (MLE). Objetivo: Evaluar la sensibilidad y la especificidad de nuestra técnica y describir las características de los pacientes para los que se solicita dicha determinación. Métodos: Los anticuerpos IgG-NMO se analizaron mediante inmunohistoquímica y se confirmaron sobre células HEK transfectadas con acuaporina 4. La información clínica se obtuvo mediante un cuestionario rellenado por el neurólogo remitente de la muestra. Resultados: Desde noviembre de 2005 a septiembre de 2008 se analizaron 580 muestras de 518 pacientes. Se obtuvo información de 358 (68%) pacientes. El seguimiento en los 33 casos positivos fue del 100%. De los 43 pacientes diagnosticados de NMO por los criterios de 2006, 28 (65%) eran positivos; la sensibilidad fue del 62,5% si se aplicaban estos criterios eliminando el resultado de IgG-NMO y del 57% aplicando los criterios de 1999, que tampoco incluyen los IgG-NMO. Se detectaron IgG-NMO en 3 (13%) de las MLE recurrentes y 2 (4%) de las NO recurrentes. No se detectaron IgG-NMO en el resto de los pacientes evaluados (96 finalmente diagnosticados de esclerosis múltiple; 80 mielitis; 28 NO no recurrentes; 33 con otros diagnósticos). Conclusiones: En este estudio no seleccionado y tan amplio, no se han detectado falsos positivos. Los casos positivos se asocian mayoritariamente con NMO y sólo en un pequeño porcentaje con NO o MLE recurrente (AU)
Introduction: The description of a highly sensitive and specific biomarker for neuromyelitis optica (NMO-IgG/aquaporin-4 antibody) extended the clinical spectrum of NMO to limited forms such as optic neuritis (ON) and longitudinally extensive myelitis (LEM). Objective: To asses the sensitivity and specificity of our assay, and to describe the clinical characteristics of the patients who were tested for NMO-IgG. Methods: NMO-IgG was analysed by immunohistochemistry and confirmed by assay on HEK cells transfected with aquaporin-4. The clinical information was obtained from forms filled in by the referring neurologists. Results: A total of 580 samples from 518 patients were analysed from November 2005 to September 2008. Clinical information was available from 358 (68%) patients. All 33 (100%) positive cases were followed up. Twenty-eight of the 43 (65%) patients diagnosed with NMO by the revised criteria of 2006 were positive; the sensitivity was 62.5% when applying the same criteria, but discounting the criterion of NMO-IgG status, or 57% when applying the criteria of 1999. NMO-IgG was detected in 3 (13%) of the recurrent LEM and 2 (4%) of the recurrent ON. NMO-IgG was not detected in the remaining patients (96 with a final diagnosis of multiple sclerosis; 80 with myelitis; 28 with non-recurrent ON; and 33 other diagnosis). Conclusions: No false positive cases were found in this large and non-selected study. NMO-IgG positive cases were mostly associated with NMO, and only in a low percentage with recurrent ON or LEM (AU)
Subject(s)
Humans , Neuromyelitis Optica/diagnosis , Aquaporin 4/antagonists & inhibitors , Biomarkers/analysis , Sensitivity and Specificity , Multiple Sclerosis/diagnosis , Optic Neuritis/diagnosis , Immunoglobulin G/immunology , Myelitis, Transverse/diagnosis , Retrospective StudiesABSTRACT
La pancreatitis autoinmune es una enfermedad recientementecaracterizada y que en la actualidad constituye un reto diagnósticoespecialmente su diferenciación con el cáncer de páncreas. Suevolución a largo plazo es poco conocida, presentándose un casoestudiado a lo largo de 14 años y mostrando su evolución clínica,bioquímica y morfológica.Paciente mujer de 54 años que debuta con un cuadro de ictericiaobstructiva y molestias abdominales inespecíficas y constataciónen la TAC de un aumento de la cabeza del páncreas, todoello sugestivo de neoplasia de páncreas. Fue intervenida evidenciándoseun aumento difuso de todo el páncreas descartándosemalignidad intraoperatoriamente, realizando únicamente colecistectomíay coledocoduodenostomía, quedando diagnosticada entoncescomo pancreatitis crónica. Durante los años posterioresfueron apareciendo diferentes procesos autoinmunes como asma,sialoadenitis y colangitis esclerosante secundaria, así como episodiosrecurrentes de ictericia e insuficiencia pancreática endocrinay exocrina. La aparición de estas complicaciones y la detección deniveles séricos elevados de IgG4 y de anticuerpos antianhidrasacarbónica II condujo a la reevaluación de la histología inicial concluyendofinalmente con el diagnóstico de pancreatitis autoinmuneal evidenciarse una infiltración linfocitaria y plasmacitariaIgG4+, así como fibrosis y flebitis obliterativa. En los últimos añosse ha añadido a las anteriores complicaciones una fibrosis retroperitonealcon hipertensión portal, varices esofágicas y esplenomegalia
Autoimmune pancreatitis is a recently characterized diseasethat still constitutes a diagnostic challenge, especially regarding differentialdiagnosis from neoplasia. Long-term outcome is poorlyknown. We herein report a case of a patient with autoimmunepancreatitis and 14 years of follow-up, and show its clinical, biochemical,and morphological characteristics.A 54-year-old female presented with obstructive jaundice andabdominal tenderness, as well as a mass at the pancreatic head ona CT scan, suggestive of pancreatic neoplasia. Surgery showed anincrease of the whole pancreas, malignancy was intraoperativelyruled out, and a cholecystectomy and choledochoduodenostomywere carried out. The diagnosis was chronic pancreatitis. Over thefollowing years different autoimmune complications developed, includingasthma, salivary gland swelling, and sclerosing cholangitis,as well as recurrent episodes of jaundice, and exocrine and endocrinepancreatic failure. The development of these complicationscombined with the demonstration of high serum levels ofIgG4 and carbonic anhydrase II led to a re-evaluation of the initialhistology of the pancreas, leading to a final diagnosis of autoimmunepancreatitis: IgG4+ lymphoplasmacytic infiltrates, fibrosis,and obliterative phlebitis. New complications developed during thelast few years: retroperitoneal fibrosis with portal hypertension,esophageal varices, and splenomegaly
Subject(s)
Autoimmune Diseases/complications , Granuloma, Plasma Cell/complications , Hypertension, Portal/complications , Retroperitoneal Fibrosis/complications , Autoimmune Diseases/diagnosis , Autoimmune Diseases , Autoimmune Diseases/surgery , Splenomegaly/etiology , Time Factors , Tomography, X-Ray Computed , Cholangiography , Cholangitis, Sclerosing/etiology , Cholecystectomy , Chronic Disease , Diagnosis, Differential , Esophageal and Gastric Varices/etiology , Follow-Up StudiesABSTRACT
OBJECTIVE: To report the frequency and type of antibodies against neuronal surface antigens (NSA-ab) in limbic encephalitis (LE). METHODS: Analysis of clinical features, neuropathologic findings, and detection of NSA-ab using immunochemistry on rat tissue and neuronal cultures in a series of 45 patients with paraneoplastic (23) or idiopathic (22) LE. RESULTS: NSA-ab were identified in 29 patients (64%; 12 paraneoplastic, 17 idiopathic). Thirteen patients had voltage-gated potassium channels (VGKC)-ab, 11 novel NSA (nNSA)-ab, and 5 NMDA receptor (NMDAR)-ab. nNSA-ab did not identify a common antigen and were more frequent in paraneoplastic than idiopathic LE (39% vs 9%; p = 0.03). When compared with VGKC-ab or NMDAR-ab, the nNSA associated more frequently with intraneuronal antibodies (11% vs 73%; p = 0.001). Of 12 patients (9 nNSA-ab, 2 VGKC-ab, 1 NMDAR-ab) with paraneoplastic LE and NSA-ab, concomitant intraneuronal antibodies occurred in 9 (75%). None of these 12 patients improved with immunotherapy. The autopsy of three of them showed neuronal loss, microgliosis, and cytotoxic T cell infiltrates in the hippocampus and amygdala. These findings were compatible with a T-cell mediated neuronal damage. In contrast, 13 of 17 (76%) patients with idiopathic LE and NSA-ab (8 VGKC-ab, 4 NMDAR-ab, 1 nNSA-ab) and 1 of 5 (20%) without antibodies had clinical improvement (p = 0.04). CONCLUSIONS: In paraneoplastic limbic encephalitis (LE), novel antibodies against neuronal surface antigens (nNSA-ab) occur frequently, coexist with antibodies against intracellular antigens, and these cases are refractory to immunotherapy. In idiopathic LE, the likelihood of improvement is significantly higher in patients with NSA-ab than in those without antibodies.
Subject(s)
Antibodies/blood , Antigens, Surface/immunology , Limbic Encephalitis/immunology , Limbic Encephalitis/pathology , Neurons/immunology , Paraneoplastic Syndromes/immunology , Aged , Aged, 80 and over , Animals , Antibodies/analysis , Brain/immunology , Brain/pathology , Cells, Cultured , Female , Humans , Immunohistochemistry , Immunotherapy , Limbic Encephalitis/mortality , Limbic Encephalitis/therapy , Male , Middle Aged , Rats , Treatment OutcomeABSTRACT
Autoimmune thyroid diseases (AITD) are considered as prototypic organ-specific autoimmune diseases, yet their underlying aetiology remains poorly understood. Among the various pathophysiological mechanisms considered, a failure of central tolerance has received little attention. Here we present evidence in favour of dysregulated thymic function playing a role in AITD. Flow-cytometric analyses conducted in peripheral blood lymphocytes from 58 AITD patients and 48 age- and-sex-matched controls showed that AITD patients have significantly higher blood levels of CD4(+)CD45RA(+), CD4(+)CD31(+) and CD4/CD8 double-positive T lymphocytes, all markers of recent thymic emigrants (RTE). In addition, the alpha-signal joint T cell receptor excision circles (TRECs) content (a molecular marker of RTEs) was higher in the group of AITD patients older than 35 years than in age-matched controls. This was independent from peripheral T cell expansion as assessed by relative telomere length. Comparisons of TREC levels in peripheral blood lymphocytes and intrathyroidal lymphocytes in paired samples showed higher levels within the thyroid during the initial 30 months of the disease, indicating an influx of RTE into the thyroid during the initial stages of AITD. Additionally, a lack of correlation between TREC levels and forkhead box P3 expression suggests that the intrathyroidal RTE are not natural regulatory T cells. These results uncover a hitherto unknown correlation between altered thymic T cell export, the composition of intrathyroidal T cells and autoimmune pathology.
Subject(s)
Autoimmune Diseases/immunology , T-Lymphocytes/metabolism , Thymus Gland/immunology , Thyroid Diseases/immunology , Adult , Age Factors , Aged , Autoimmune Diseases/blood , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Humans , Male , Middle Aged , Self Tolerance , Spain , T-Lymphocytes/immunology , Telomere/pathology , Thymus Gland/physiopathology , Thyroid Diseases/blood , Young AdultABSTRACT
Antibodies against neuronal surface antigens (NSA-ab) have been described in pediatric opsoclonus-myoclonus syndrome (OMS). We analyzed the presence of NSA-ab by flow cytometry and immunocytochemistry of live cerebellar granular neurons (CGN) in the serum of 25 adult patients with idiopathic (14) and paraneoplastic (11) OMS. Paraneoplastic, but not idiopathic, OMS sera showed a CGN surface binding by flow cytometry higher than that of controls (mean MFI (median fluorescence intensity): 29+/-6.9 vs. 20+/-5.8; p=0.001) but only one serum had a binding greater than three standard deviations of controls. OMS sera did not label live CGN by immunocytochemistry. Unlike pediatric OMS, NSA-ab were not detected in adult cases suggesting that the immunity to NSA in OMS is heterogeneous.
Subject(s)
Antibodies/metabolism , Antigens, Surface/immunology , Neurons/immunology , Opsoclonus-Myoclonus Syndrome/immunology , Adult , Aged , Animals , Cells, Cultured , Female , Flow Cytometry/methods , Humans , Male , Middle Aged , Rats , Rats, WistarABSTRACT
BACKGROUND/OBJECTIVE: We reported that 43% of patients with Lambert-Eaton myasthenic syndrome (LEMS) and small cell lung cancer (SCLC) had an antibody called anti-glial nuclear antibody (AGNA), defined by the immunoreaction with the nuclei of the Bergmann glia of the cerebellum. This study was undertaken to identify the antigen recognized by AGNA and to confirm the association with paraneoplastic LEMS in a larger series. METHODS: We probed a fetal brain cDNA library with AGNA-positive sera. The presence of antibodies against the isolated antigen was detected by immunoblot of phage plaques from two positive clones. We studied 105 patients with LEMS (55 with SCLC), 50 with paraneoplastic neurologic syndromes, SCLC, and Hu antibodies, and 50 with only SCLC. RESULTS: Probing of the fetal brain expression library with AGNA sera resulted in the isolation of SOX1, a highly immunogenic tumor antigen in SCLC. IgG eluted from SOX1 clones produced the same cerebellar immunoreactivity as of AGNA sera. SOX1 antibodies were present in 64% of patients with LEMS and SCLC but in none of the 50 with idiopathic LEMS (p < 0.0001). Compared with paraneoplastic LEMS, the frequency of SOX1 antibodies was significantly lower in patients with Hu antibodies (32%, p = 0.002) and in those with only SCLC (22%). CONCLUSIONS: SOX1 is the antigen recognized by anti-glial nuclear antibody-positive sera. The detection of SOX1 antibodies in patients with Lambert-Eaton myasthenic syndrome (LEMS) predicts the presence of small cell lung cancer and may be used to follow more closely those LEMS patients with no evidence of cancer at the initial workup.
Subject(s)
Autoantibodies/blood , Carcinoma, Small Cell/immunology , DNA-Binding Proteins/immunology , High Mobility Group Proteins/immunology , Lambert-Eaton Myasthenic Syndrome/complications , Lambert-Eaton Myasthenic Syndrome/immunology , Lung Neoplasms/immunology , Aged , Animals , Antigens, Neoplasm/immunology , Autoantibodies/analysis , Biomarkers/analysis , Biomarkers/blood , Biomarkers, Tumor/analysis , Biomarkers, Tumor/blood , Biomarkers, Tumor/immunology , Calcium Channels/immunology , Carcinoma, Small Cell/diagnosis , Cerebellum/cytology , Cerebellum/immunology , Female , Humans , Immunoblotting , Lambert-Eaton Myasthenic Syndrome/diagnosis , Lung Neoplasms/diagnosis , Male , Neuroglia/immunology , Paraneoplastic Syndromes/diagnosis , Paraneoplastic Syndromes/immunology , Predictive Value of Tests , Prognosis , Rats , SOXB1 Transcription FactorsABSTRACT
Autoimmune pancreatitis is a recently characterized disease that still constitutes a diagnostic challenge, especially regarding differential diagnosis from neoplasia. Long-term outcome is poorly known. We herein report a case of a patient with autoimmune pancreatitis and 14 years of follow-up, and show its clinical, biochemical, and morphological characteristics. A 54-year-old female presented with obstructive jaundice and abdominal tenderness, as well as a mass at the pancreatic head on a CT scan, suggestive of pancreatic neoplasia. Surgery showed an increase of the whole pancreas, malignancy was intraoperatively ruled out, and a cholecystectomy and choledochoduodenostomy were carried out. The diagnosis was chronic pancreatitis. Over the following years different autoimmune complications developed, including asthma, salivary gland swelling, and sclerosing cholangitis, as well as recurrent episodes of jaundice, and exocrine and endocrine pancreatic failure. The development of these complications combined with the demonstration of high serum levels of IgG4 and carbonic anhydrase II led to a re-evaluation of the initial histology of the pancreas, leading to a final diagnosis of autoimmune pancreatitis: IgG4+ lymphoplasmacytic infiltrates, fibrosis, and obliterative phlebitis. New complications developed during the last few years: retroperitoneal fibrosis with portal hypertension, esophageal varices, and splenomegaly.
Subject(s)
Autoimmune Diseases/complications , Granuloma, Plasma Cell/complications , Hypertension, Portal/complications , Pancreatitis, Chronic/complications , Retroperitoneal Fibrosis/complications , Autoimmune Diseases/diagnosis , Autoimmune Diseases/diagnostic imaging , Autoimmune Diseases/pathology , Autoimmune Diseases/surgery , Cholangiography , Cholangitis, Sclerosing/etiology , Cholecystectomy , Chronic Disease , Diagnosis, Differential , Esophageal and Gastric Varices/etiology , Female , Follow-Up Studies , Humans , Liver/pathology , Middle Aged , Pancreas/pathology , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/diagnostic imaging , Pancreatitis, Chronic/pathology , Pancreatitis, Chronic/surgery , Radiography, Abdominal , Splenomegaly/etiology , Time Factors , Tomography, X-Ray ComputedABSTRACT
Parathyroid carcinoma (PC) is an infrequent disease with a subtle initial presentation and a variable course, necessitating a high index of suspicion to make the correct diagnosis. In chronic failure patients on haemodialysis it becomes even more difficult to suspect this entity since the high prevalence of secondary hyperparathyroidism(SHP). Two patients with PC out of a series of 160 patients with moderate-to-severe SHP submitted for parathyroidectomy are reported. Their clinical features are compared with those of the twenty-two cases previously reported in the literature with a discussion of this pathology. Patients with PC showed higher blood levels of iPTH, total calcium, phosphate and total alkaline phosphatase than the SHP population. The final diagnosis of PC was made after histological study revealing capsular or blood vessel invasion.